Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.235 USD | -3.40% | -12.30% | +52.96% |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+52.96% | 518M | - | ||
+12.24% | 2.89B | D+ | ||
-7.14% | 1.37B | - | ||
-5.91% | 441M | - | ||
-5.29% | 92.27M | - | - | |
-20.67% | 82.77M | - | ||
+32.02% | 53.31M | - | - | |
+23.87% | 57M | - | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- GLASF Stock
- Ratings Glass House Brands Inc.